New combo shows promise for rare eye cancer, but not a cure
NCT ID NCT05282901
First seen Dec 12, 2025 · Last updated May 12, 2026 · Updated 16 times
Summary
This study tests two drugs, pembrolizumab and lenvatinib, in people with a rare eye cancer that has spread (metastatic uveal melanoma). The goal is to see if the combination can slow or stop tumor growth. About 51 adults are taking part, and they will be monitored with scans every 9 weeks. This is not a cure; patients may need ongoing treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC UVEAL MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institut Curie
Paris, 75005, France
Conditions
Explore the condition pages connected to this study.